Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation

Dicitore, Alessandra; Grassi, Elisa; Borghi, Maria Orietta; Gelmini, Giulia; Cantone, Maria Celeste; Gaudenzi, Germano; Persani, Luca; Caraglia, Michele; Mantovani, Giovanna

doi:10.1007/s40618-017-0631-0

Cited by 10 publications

(11 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study has some limitations. We did not evaluate the potential effects of PDE5i treatment on cytokines (i.e., IFN-β) involved in the modulation of cell proliferation and differentiation of CRPC [63]. Furthermore, it was clear that the cotreatment of TAD and BCT strongly reverted the stimulation of Cyp19a1, but further studies aimed to clarify mechanism/s explaining enhancement of ADT by TAD are needed to evaluate the antitumor potential of these two molecules, and their role on the estrogen receptors function.…”

Section: Discussionmentioning

confidence: 99%

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line

Bimonte

Marampon

Antonioni

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Background: The androgen receptor (AR) plays a key role in normal prostate homeostasis and in prostate cancer (PCa) development, while the role of aromatase (Cyp19a1) is still unclear. We evaluated the effects of a treatment with Tadalafil (TAD) on both these proteins. Methods: Androgen-sensitive human PCa cell line (LnCAP) was incubated with/without TAD (10−6 M) and bicalutamide (BCT) (10−4 M) to evaluate a potential modulation on cell proliferation, protein and mRNA expression of Cyp19a, AR and estrogen receptor-β (ERβ), respectively. Results: TAD increased early AR nuclear translocation (p < 0.05, after 15 min of exposure), and increased AR transcriptional activity (p < 0.05) and protein expression (p < 0.05) after 24 h. Moreover, after 24 h this treatment upregulated Cyp19a1 and ERβ mRNA (p < 0.05 and p < 0.005 respectively) and led to an increase in protein expression of both after 48 h (p < 0.05). Interestingly, TAD counteracted Cyp19a1 stimulation induced by BCT (p < 0.05) but did not alter the effect induced by BCT on the AR protein expression. Conclusion: We demonstrate for the first time that TAD can significantly modulate AR expression and activity, Cyp19a1 and ERβ expression in PCa cells, suggesting a specific effect of these proteins. In addition, TAD potentiates the antiproliferative activity of BCT, opening a new clinical scenario in the treatment of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line

Bimonte

Marampon

Antonioni

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Down-regulated expression of proteins induced by IFNs in human prostate epithelial cells has been reported to be associated with development and progression of PCa (35,36). IFN-β1a showed significant anti-proliferative activity in androgen-resistant cell lines (37). Recombinant human IFNβ (rHuIFN-β) reduced the motility and invasiveness of poorly differentiated PCa cells and prevented the acquisition of a neuroendocrine phenotype (38).…”

Section: Discussionmentioning

confidence: 99%

“…The growth inhibitory effect of IFNs on PCa has been previously observed. IFN-β treatment of PCa cells has been shown to inhibit their proliferation (16,17). Furthermore, the down-regulation of the expression of IFN-inducible proteins in prostate epithelial cells is associated with the development and progression of prostate cancer (18).…”

mentioning

confidence: 99%

MiR-139 Induces an Interferon-β Response in Prostate Cancer Cells by Binding to RIG-1

Nam

Benatar

Amemiya

et al. 2021

Cancer Genomics Proteomics

View full text Add to dashboard Cite

“…Hormone therapy, or androgen ablation therapy, is considered the first-line clinical treatment for patients with metastatic disease; however, in the majority of cases, the effect of androgen deprivation is temporary ( 2 ). Subsequently, these patients ultimately become insensitive to androgen ablation, and hormone-refractory prostate cancer (HRPC) develops after 18–24 months of conventional treatment ( 3 ). HRPC is a common type of malignant, metastatic tumor with poor prognosis, common recurrence and a high fatality rate ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

CLC-3 and SOX2 regulate the cell cycle in DU145 cells

Chen

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Sex determining region Y-box 2 (SOX2) is a transcription factor that serves a role in numerous different types of malignant cancer. Altered expression of chloride channel proteins has been described in a variety of malignancies. However, the association between SOX2 and chloride channel proteins is not yet fully understood. The present study investigated the association between SOX2 and chloride voltage-gated channel 3 (CLC-3) in prostate cancer. Flow cytometry demonstrated that the inactivation of CLC-3 or SOX2 arrested cell cycle progression in the G 0 /G 1 phase. Furthermore, CLC-3 was observed to bind to SOX2, and vice versa, by co-immunoprecipitation. SOX2 appears to initiate and maintain prostate cancer tumorigenesis, in part, by modulating the cell cycle. These findings indicate the potential of SOX2 and CLC-3 as targets for the development of multi-targeted therapeutics.

show abstract

Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation

Abstract: Recombinant IFN-β1a (Rebif) showed a potent in vitro anti-proliferative activity in androgen-resistant prostate cancer cells, and it could represent a promising tool for the treatment of this tumor.

Cited by 10 publications

References 52 publications

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line

MiR-139 Induces an Interferon-β Response in Prostate Cancer Cells by Binding to RIG-1

CLC-3 and SOX2 regulate the cell cycle in DU145 cells

Contact Info

Product

Resources

About